The main purpose of the study is to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Name: Cisplatin
Description: Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).Type: DrugCohort A: Cisplatin or Carboplatin + Pemetrexed + M7824 Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824
Name: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).Type: DrugCohort A: Cisplatin or Carboplatin + Pemetrexed + M7824
Name: Pemetrexed
Description: Pemetrexed will be administered intravenously at a dose of 500 mg/ m^2 over 10 minutes every 21 days.Type: DrugCohort A: Cisplatin or Carboplatin + Pemetrexed + M7824
Name: Nab-paclitaxel
Description: Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).Type: DrugCohort B: Carboplatin + Nab-paclitaxel + M7824
Name: Gemcitabine
Description: Gemcitabine will be administered intravenously at a dose of 1250 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).Type: DrugCohort C: Cisplatin or Carboplatin + Gemcitabine + M7824
Name: Docetaxel
Description: Docetaxel will be administered intravenously at a dose of 75 mg/m^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).Type: DrugCohort D: Docetaxel + M7824
Name: M7824
Description: M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.Type: DrugCohort A: Cisplatin or Carboplatin + Pemetrexed + M7824
Name: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).Type: DrugCohort B: Carboplatin + Nab-paclitaxel + M7824
Name: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).Type: DrugCohort C: Cisplatin or Carboplatin + Gemcitabine + M7824
Name: M7824
Description: M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.Type: DrugCohort B: Carboplatin + Nab-paclitaxel + M7824 Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824 Cohort D: Docetaxel + M7824
Allocation: Non-Randomized
Parallel Assignment
There is one SNP
Fresh biopsies should be collected if archived tumor material is not available - Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry and date of first dose Exclusion Criteria: - The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation, if targeted therapy is locally approved - Mixed small cell with non-small cell lung cancer histology - Has received major surgery within 4 weeks prior to the first dose of study intervention; received thoracic radiation therapy (RT) of > 30 gray (Gy) within 6 months prior to the first dose of study intervention - Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. --- V600E ---